Replies to post #74088 on Anavex Life Sciences Corp (AVXL)

[Amatuer17]

Here is my take on situation -

AVXL was on high ride based on field results and 5 week data that kind of indicated that it is safe and effective.

Based on these early indication, it was presumed that A2-73 can go into shorter adaptive trials leading to faster path of approval.

However recent data showed that - it is safe but may not be as effective as was touted - further in presence of D it seems ineffective (no conclusion)

This means - company has to make decision on going as monotherapy in which case they will have to a smaller trial to confirm efficacy and then go for larger P3 trial like BIIB Or Lily.

All this means it has added few years to the trial cycles and not easy to get partners. This in turn means few years for spend and dilution without concrete catalyst.

So while product remains promising - the investment becomes locked for longer period with low returns.

This has caused lack of interest and price is remaining low.